Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activates Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia

Karina Calvopiña, Punyawee Dulyayangkul, Matthew B. Avison
Karina Calvopiña
aSchool of Cellular & Molecular Medicine, University of Bristol, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Punyawee Dulyayangkul
aSchool of Cellular & Molecular Medicine, University of Bristol, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew B. Avison
aSchool of Cellular & Molecular Medicine, University of Bristol, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew B. Avison
DOI: 10.1128/AAC.01524-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Aminoglycoside resistance in Stenotrophomonas maltophilia is multifactorial, but the most significant mechanism is overproduction of the SmeYZ efflux system. By studying laboratory-selected mutants and clinical isolates, we show here that damage to the 50S ribosomal protein L1 (RplA) activates SmeYZ production. We also show that gentamicin and minocycline, which target the ribosome, induce expression of smeYZ. These findings explain the role of SmeYZ in both intrinsic and mutationally acquired aminoglycoside resistance.

TEXT

Aminoglycoside resistance in the important opportunistic pathogen Stenotrophomonas maltophilia is multifactorial. Reduced amikacin and tobramycin susceptibility is conferred by a chromosomal aac(6′)-Iz gene, which is present in approximately 50% of clinical isolates (1, 2). The chromosomal aph(3′)-IIc gene is more widespread among S. maltophilia clinical isolates and is responsible for reduced kanamycin and neomycin susceptibility (3). A wide variety of other genes have been shown to play minor roles in intrinsic aminoglycoside susceptibility (4–9), but by far, the most significant inducible resistance mechanisms is the SmeYZ efflux system, where SmeZ is an RND-type efflux pump (10). Following mutation, smeYZ can be overexpressed, which leads to hyperresistance to all aminoglycosides, and, most importantly, smeYZ-overexpressing mutants have been seen in the clinic (10). Disruption of smeYZ also affects S. maltophilia virulence (11), suggesting a more pleotropic role in physiology, as is common for RND-type efflux systems (12).

It has been shown that smeYZ expression is controlled by a two-component regulatory system encoded immediately upstream, named SmeSyRy (13). One S. maltophilia aminoglycoside hyperresistant mutant shown to overexpress smeYZ is K M5 (10, 14). This mutant is a derivative of the clinical S. maltophilia isolate K279a (15, 16) and was selected for its ability to grow on amikacin at 4 times the MIC (14). In an attempt to identify the mutation responsible for smeYZ overexpression in K M5, we resurrected it from the freezer and first confirmed using CLSI disc susceptibility testing (17) that it expresses a “resistance profile 3” phenotype, as previously defined (10, 14): particularly, reduced zone diameters for aminoglycosides, quinolones, and tetracyclines (Table 1). Both SmeY and SmeZ were found to be approximately 8-fold upregulated in K M5 relative to expression in the parental strain, K279a, according to liquid chromatography tandem mass spectrometry (LC-MS/MS) envelope proteomics (Fig. 1), which was carried out as described previously (18). Whole-genome sequencing (WGS) was performed and analyzed as described before (19) and showed that smeSy and smeRy are wild type in K M5. Instead, there is only one difference from K279a, confirmed by PCR sequencing using the primers rplA F, 5′-GCGAAGGAACCGGATCTGA-3′, and rplA R, 5′-CGCCTGCGGTCTTTGAC-3′. The single point mutation in K M5 is predicted to cause a Gly67Asp change in the largest protein from the 50S ribosomal subunit, L1, encoded by the rplA gene. The previously described clinical isolate 9189, which also has the resistance profile 3 phenotype (Table 1) and overexpresses smeYZ (10), was found by PCR sequencing to also carry differences in rplA relative to that in K279a: predicted to cause a Phe22Leu change in RplA and a frameshift mutation at codon 212 caused by the insertion of a single adenine base. To confirm a role for the observed rplA mutation in reduced aminoglycoside susceptibility in K M5, wild-type rplA was amplified alongside the overlapping rplK by PCR using the primers rplAK F, 5′- AAAGCGGCCGCATCCAGCTGTAGAGTCGAGC-3′, and rplAK R, 5′- AAAGCGGCCGCCTGCGGTCTTTGACGGCTAC-3′, cut with NotI (introduced site underlined) and ligated into the broad host range vector pBBR1MCS (20), and the recombinant or empty vector was used to transform K M5 to chloramphenicol resistance (30 μg/ml). Using MIC and disc susceptibility testing, we confirmed that carriage of wild-type rplA by K M5 increased amikacin and gentamicin susceptibility relative to that of the plasmid-only control, though not to wild-type levels (Table 2, Fig. 2A). The other markers of resistance profile 3, reduced susceptibility to fluoroquinolones and tetracyclines, were not reversed by complementation of the rplA mutation in K M5, and we have previously shown that this part of the phenotype is due to the overexpression of a different pump operon, smeIJK (10). Surprisingly, in fact, fluoroquinolone and tetracycline susceptibility was reduced in K M5(pBBR1MCS::rplA) compared to that for the plasmid-only control (Fig. 2A). It is known that there is an inverse correlation between SmeYZ production and SmeDEF production in S. maltophilia (21), and indeed, proteomics confirmed that, as well as SmeY production (Fig. 2B) being reduced in K M5(pBBR1MCS::rplA) relative to that for the plasmid-only control (though not to wild-type levels, as seen for aminoglycoside MICs [Table 2]), production of SmeD, SmeE, and SmeF increased 17.3-fold, 11.2-fold, and 17.3-fold, respectively (P < 0.001, n = 3 for all). SmeDEF is a known tripartite efflux pump for fluoroquinolones and tetracyclines in S. maltophilia (22), explaining our findings (Fig. 2A).

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1

Disc susceptibility profile of S. maltophilia derivatives and clinical isolates

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Production of SmeYZ in K M5. Protein abundance data for whole-envelope proteomics were normalized to the average 30S and 50S ribosomal protein abundance for each. Abundance of SmeY and SmeZ (UniProt B2FQ54 and B2FQ55) are reported as means ± standard errors of the means (SEMs), n = 3. Differences between K279a and K M5 were statistically significant (P < 0.05).

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 2

Aminoglycoside MICs against S. maltophilia derivatives and clinical isolates

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Effect of complementing K M5 with rplA. (A) Disc susceptibility testing for antimicrobials against K M5 carrying pBBR1MCS alone or pBBR1MCS::rplA. Data are means ± SEMs, n = 3. LEV, levofloxacin, 5 μg disc; CIP, ciprofloxacin, 5 μg disc; MH, minocycline, 30 μg disc; TE, tetracycline, 30 μg disc; CN, gentamicin, 10 μg disc; AK, amikacin, 10 μg disc; SXT, sulfamethoxazole-trimethoprim, 25 μg disc. (B) Abundances of SmeY normalized to average ribosomal protein abundances based on proteomics analysis is reported as means ± SEMs, n = 3. The differences between K279a and K M5 and between K M5(pBBR1MCS) and K M5(pBBR1MCS::rplA) are statistically significant (P < 0.05).

In Pseudomonas aeruginosa, MexXY is considered the most important efflux pump involved in aminoglycoside resistance (23). It has been stated that at least two P. aeruginosa clinical isolates that hyperexpress mexXY have truncations in rplA, though the data were not presented and were reported as “unpublished” (24). Mutations in other ribosomal subunit genes have more conclusively been shown to cause mexXY overexpression (25). Given the similarities between MexXY and SmeYZ, this provides precedence for our experimental observation that rplA disruption is the cause of smeYZ overexpression in S. maltophilia.

Expression of mexXY in P. aeruginosa is inducible in response to ribosomal acting antibiotics (25, 26), and since ribosomal protein damage by mutation is associated with SmeYZ overproduction in S. maltophilia (Fig. 1), we next tested the inducibility of smeZ expression by the ribosomal acting antibiotics gentamicin and minocycline. Expression of smeZ was assessed by reverse transcriptase quantitative PCR (RT-qPCR) using RNA prepared from a nutrient broth (NB) culture of K279a exposed to gentamicin (32 μg/ml) or minocycline (0.5 μg/ml) versus untreated control. The method used was as described previously (18) with the primers smeZ RT F, 5- TGTCCAGCGTCAAGCACC-3, and smeZ RT R, 5- GCCGACCAGCATCAGGAAG-3. Abundance of smeZ was normalized to rrnB abundance (as an RNA loading control) using the primers rrnB F, 5- GACCTTGCGCGATTGAATG-3, and rrnB R, 5- CGGATCGTCGCCTTGGT-3. This experiment confirmed that, as predicted, the normalized expression of smeZ in the gentamicin- or minocycline-treated K279a cultures was significantly more (approximately 8-fold and 3-fold, respectively, P < 0.05, n=3 biological replicates, each with 4 technical replicates) than in the control (Fig. 3).

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

RT-qPCR analysis of the effect of ribosomal acting antibiotics on smeZ expression in K279a. K279a cultures were diluted 1:100 from an overnight culture and each grown in NB for 3 h. The experimental group was grown in the presence of gentamicin (CN) (32 μg/ml) or minocycline (MH) (0.5 μg/ml). RNA was purified and the abundance of smeZ in each RNA preparation was assayed using RT-qPCR calculated using the threshold cycle (2ΔΔCT) method (18) using the rrnB gene as an internal control for RNA abundance. Values for the smeZ/rrnB ratio from treated cells were normalized to those of the untreated control (NB). *, P < 0.05 versus control. There were three biological and, for each, four technical replicates.

Based on our findings, we therefore conclude that RplA damage in S. maltophilia constitutively mimics the effects of treatment with ribosomal acting antibiotics and constitutively activates SmeYZ production, raising aminoglycoside MICs. Our finding that rplA mutations exist in SmeYZ-overproducing clinical isolates confirms that such a mutation does not impair fitness or virulence so much that the mutants cannot survive, colonize, and cause infections in humans. Indeed, since reduced SmeYZ production reduces S. maltophilia virulence, at least in vitro and in a mouse model of infection (11), it may be that the advantage of rplA mutation in S. maltophilia is greater than simply raising aminoglycoside MICs. Given that S. maltophilia is frequently a colonizer of the lungs of cystic fibrosis patients, for which the aminoglycoside tobramycin is a regular therapy (27), the potential for selecting mutants with elevated SmeYZ production seems high.

ACKNOWLEDGMENTS

This work was funded by grants MR/N013646/1 and MR/S004769/1 to M.B.A. from the Antimicrobial Resistance Cross Council Initiative supported by the seven United Kingdom research councils. K.C. received a postgraduate scholarship from SENESCYT, Ecuador.

We thank Kate Heesom, School of Biochemistry, University of Bristol, for performing the proteomics analysis.

We declare no conflicts of interest.

FOOTNOTES

    • Received 28 July 2019.
    • Returned for modification 28 August 2019.
    • Accepted 24 October 2019.
    • Accepted manuscript posted online 11 November 2019.
  • Copyright © 2020 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Lambert T,
    2. Ploy MC,
    3. Denis F,
    4. Courvalin P
    . 1999. Characterization of the chromosomal aac(6′)-Iz gene of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 43:2366–2371. doi:10.1128/AAC.43.10.2366.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Li XZ,
    2. Zhang L,
    3. McKay GA,
    4. Poole K
    . 2003. Role of the acetyltransferase AAC(6′)-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J Antimicrob Chemother 51:803–811. doi:10.1093/jac/dkg148.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Okazaki A,
    2. Avison MB
    . 2007. Aph(3′)-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 51:359–360. doi:10.1128/AAC.00795-06.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Huang YW,
    2. Hu RM,
    3. Yang TC
    . 2013. Role of the pcm-tolCsm operon in the multidrug resistance of Stenotrophomonas maltophilia. J Antimicrob Chemother 68:1987–1993. doi:10.1093/jac/dkt148.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Lin CW,
    2. Huang YW,
    3. Hu RM,
    4. Yang TC
    . 2014. SmeOP-TolCSm efflux pump contributes to the multidrug resistance of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 58:2405–2408. doi:10.1128/AAC.01974-13.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Lin YT,
    2. Huang YW,
    3. Liou RS,
    4. Chang YC,
    5. Yang TC
    . 2014. MacABCsm, an ABC-type tripartite efflux pump of Stenotrophomonas maltophilia involved in drug resistance, oxidative and envelope stress tolerances and biofilm formation. J Antimicrob Chemother 69:3221–3226. doi:10.1093/jac/dku317.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Wu CJ,
    2. Huang YW,
    3. Lin YT,
    4. Yang TC
    . 2016. Inactivation of lytic transglycosylases increases susceptibility to aminoglycosides and macrolides by altering the outer membrane permeability of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 60:3236–3239. doi:10.1128/AAC.03026-15.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Liu MC,
    2. Tsai YL,
    3. Huang YW,
    4. Chen HY,
    5. Hsueh PR,
    6. Lai SY,
    7. Chen LC,
    8. Chou YH,
    9. Lin WY,
    10. Liaw SJ
    . 2016. Stenotrophomonas maltophilia PhoP, a two-component response regulator, involved in antimicrobial susceptibilities. PLoS One 11:e0153753. doi:10.1371/journal.pone.0153753.
    OpenUrlCrossRef
  9. 9.↵
    1. Huang HH,
    2. Lin YT,
    3. Chen PY,
    4. Li LH,
    5. Ning HC,
    6. Yang TC
    . 2018. ClpA and HtpX proteases are involved in intrinsic aminoglycoside resistance of Stenotrophomonas maltophilia and are potential aminoglycoside adjuvant targets. Antimicrob Agents Chemother 62:e00554-18. doi:10.1128/AAC.00554-18.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Gould VC,
    2. Okazaki A,
    3. Avison MB
    . 2013. Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 57:655–657. doi:10.1128/AAC.01020-12.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Lin YT,
    2. Huang YW,
    3. Chen SJ,
    4. Chang CW,
    5. Yang TC
    . 2015. The SmeYZ efflux pump of Stenotrophomonas maltophilia contributes to drug resistance, virulence-related characteristics, and virulence in mice. Antimicrob Agents Chemother 59:4067–4073. doi:10.1128/AAC.00372-15.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Piddock LJ
    . 2006. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol 4:629–636. doi:10.1038/nrmicro1464.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Wu CJ,
    2. Huang YW,
    3. Lin YT,
    4. Ning HC,
    5. Yang TC
    . 2016. Inactivation of SmeSyRy two-component regulatory system inversely regulates the expression of SmeYZ and SmeDEF efflux pumps in Stenotrophomonas maltophilia. PLoS One 11:e0160943. doi:10.1371/journal.pone.0160943.
    OpenUrlCrossRef
  14. 14.↵
    1. Gould VC,
    2. Avison MB
    . 2006. SmeDEF-mediated antimicrobial drug resistance in Stenotrophomonas maltophilia clinical isolates having defined phylogenetic relationships. J Antimicrob Chemother 57:1070–1076. doi:10.1093/jac/dkl106.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Avison MB,
    2. von Heldreich CJ,
    3. Higgins CS,
    4. Bennett PM,
    5. Walsh TR
    . 2000. A TEM-2beta-lactamase encoded on an active Tn1-like transposon in the genome of a clinical isolate of Stenotrophomonas maltophilia. J Antimicrob Chemother 46:879–884. doi:10.1093/jac/46.6.879.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Crossman LC,
    2. Gould VC,
    3. Dow JM,
    4. Vernikos GS,
    5. Okazaki A,
    6. Sebaihia M,
    7. Saunders D,
    8. Arrowsmith C,
    9. Carver T,
    10. Peters N,
    11. Adlem E,
    12. Kerhornou A,
    13. Lord A,
    14. Murphy L,
    15. Seeger K,
    16. Squares R,
    17. Rutter S,
    18. Quail MA,
    19. Rajandream MA,
    20. Harris D,
    21. Churcher C,
    22. Bentley SD,
    23. Parkhill J,
    24. Thomson NR,
    25. Avison MB
    . 2008. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol 9:R74. doi:10.1186/gb-2008-9-4-r74.
    OpenUrlCrossRefPubMed
  17. 17.↵
    Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial disk susceptibility tests, 9th. Approved Standard M2-A9.CLSI, Wayne, PA.
  18. 18.↵
    1. Jiménez-Castellanos JC,
    2. Wan Nur Ismah WAK,
    3. Takebayashi Y,
    4. Findlay J,
    5. Schneiders T,
    6. Heesom KJ,
    7. Avison MB
    . 2018. Envelope proteome changes driven by RamA overproduction in Klebsiella pneumoniae that enhance acquired β-lactam resistance. J Antimicrob Chemother 73:88–94. doi:10.1093/jac/dkx345.
    OpenUrlCrossRef
  19. 19.↵
    1. Calvopiña K,
    2. Avison MB
    . 2018. Disruption of mpl activates β-lactamase production in Stenotrophomonas maltophilia and Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 62:e00638-18. doi:10.1128/AAC.00638-18.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Obranić S,
    2. Babić F,
    3. Maravić-Vlahoviček G
    . 2013. Improvement of pBBR1MCS plasmids, a very useful series of broad-host-range cloning vectors. Plasmid 70:263–267. doi:10.1016/j.plasmid.2013.04.001.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Huang YW,
    2. Lin CW,
    3. Ning HC,
    4. Lin YT,
    5. Chang YC,
    6. Yang TC
    . 2017. Overexpression of SmeDEF efflux pump decreases aminoglycoside resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 61:e02685-16. doi:10.1128/AAC.02685-16.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Alonso A,
    2. Martínez JL
    . 2000. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 44:3079–3086. doi:10.1128/aac.44.11.3079-3086.2000.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Lau CH,
    2. Fraud S,
    3. Jones M,
    4. Peterson SN,
    5. Poole K
    . 2012. Reduced expression of the rplU-rpmA ribosomal protein operon in mexXY-expressing pan-aminoglycoside-resistant mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 56:5171–5179. doi:10.1128/AAC.00846-12.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Westbrock-Wadman S,
    2. Sherman DR,
    3. Hickey MJ,
    4. Coulter SN,
    5. Zhu YQ,
    6. Warrener P,
    7. Nguyen LY,
    8. Shawar RM,
    9. Folger KR,
    10. Stover CK
    . 1999. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother 43:2975–2983. doi:10.1128/AAC.43.12.2975.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Jeannot K,
    2. Sobel ML,
    3. El Garch F,
    4. Poole K,
    5. Plésiat P
    . 2005. Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug-ribosome interaction. J Bacteriol 187:5341–5346. doi:10.1128/JB.187.15.5341-5346.2005.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Morita Y,
    2. Sobel ML,
    3. Poole K
    . 2006. Antibiotic inducibility of the MexXY multidrug efflux system of Pseudomonas aeruginosa: involvement of the antibiotic-inducible PA5471 gene product. J Bacteriol 188:1847–1855. doi:10.1128/JB.188.5.1847-1855.2006.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Ratjen A,
    2. Yau Y,
    3. Wettlaufer J,
    4. Matukas L,
    5. Zlosnik JE,
    6. Speert DP,
    7. LiPuma JJ,
    8. Tullis E,
    9. Waters V
    . 2015. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob Agents Chemother 59:711–713. doi:10.1128/AAC.04123-14.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activates Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia
Karina Calvopiña, Punyawee Dulyayangkul, Matthew B. Avison
Antimicrobial Agents and Chemotherapy Jan 2020, 64 (2) e01524-19; DOI: 10.1128/AAC.01524-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activates Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activates Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia
Karina Calvopiña, Punyawee Dulyayangkul, Matthew B. Avison
Antimicrobial Agents and Chemotherapy Jan 2020, 64 (2) e01524-19; DOI: 10.1128/AAC.01524-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

efflux
gentamicin
ribosomal mutations

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596